10-K: Theriva Biologics Reports 2024 Results, Focuses on Oncolytic Virus Pipeline

Theriva Biologics transitions strategic focus to oncology, developing oncolytic adenovirus platform while exploring options for gastrointestinal assets.

Summary

• Theriva Biologics is a clinical-stage company shifting its focus to oncology, particularly the development of its oncolytic adenovirus platform.
• The company is exploring value creation options, including out-licensing or partnering, for its gastrointestinal assets SYN-004 and SYN-020.
• The lead product candidate, VCN-01, is in a Phase 2 clinical study for pancreatic cancer and has been used in Phase 1 studies for retinoblastoma and other solid tumors.
• The company completed a public offering in September 2024, raising approximately $2.5 million before deducting fees.
• A research and development tax credit of $1.4 million was recognized for the year ended December 31, 2024.
• The net loss for the year ended December 31, 2024, was $25.7 million, or ($19.03) per common share.
• The company's cash and cash equivalents were $11.6 million as of December 31, 2024, expected to fund operations into the third quarter of 2025.
• The company is actively pursuing additional equity or debt financing.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in the clinical pipeline, the company's financial situation raises concerns about its ability to continue as a going concern.

Positives

• The VIRAGE Phase 2b clinical trial for VCN-01 in pancreatic cancer completed target patient enrollment, with topline data expected in Q2 2025.
• The company had a Type D meeting with the FDA to discuss Phase 3 clinical study design for VCN-01 in pancreatic cancer.
• The company received Scientific Advice from the EMA on the design of a Phase 3 clinical study of VCN-01 in combination with standard-of-care chemotherapy for the treatment of metastatic PDAC.
• Positive topline data was announced from a Phase 1 trial of intravitreal VCN-01 in patients with retinoblastoma.
• The company received Rare Pediatric Drug Designation (RPDD) for VCN-01 for the treatment of retinoblastoma.
• The company recognized a $1.4 million research and development tax credit for the year ended December 31, 2024.

Negatives

• The company has a history of losses and a significant accumulated deficit.
• The company's auditors report contains an explanatory paragraph regarding its ability to continue as a going concern.
• The company will need to raise additional capital to operate its business.
• The company experienced a sustained decline in the quoted market price of its Common Stock and recorded IPRD and Goodwill impairment charges of $1.3 million and $5.6 million, respectively.
• The net loss for the year ended December 31, 2024, was $25.7 million, or ($19.03) per common share.

Risks

• The company's auditors report contains an explanatory paragraph regarding its ability to continue as a going concern.
• The company will need to raise additional capital to operate its business, and failure to obtain funding may force delays or elimination of development programs.
• The company has a limited operating history as an oncology company and no products approved for commercial sale.
• The company's operating results may fluctuate significantly, making future results difficult to predict.
• Developments by competitors may render the company's products or technologies obsolete.
• The company relies extensively on information technology systems, which are vulnerable to cybersecurity and data leakage risks.
• Clinical trials are expensive, time-consuming, and difficult to design and implement.
• The results of clinical trials may not support proposed product candidate claims.
• The company relies on patent applications and regulatory exclusivities to protect its product candidates, and its ability to compete may be limited if it cannot protect its products.
• The market price of the company's common stock has been and may continue to be volatile.

Future Outlook

The company expects to continue to incur significant operating and capital expenditures and will need additional funds to support its operations. Topline data for the VIRAGE Phase 2b clinical trial is anticipated for Q2 2025.

Industry Context

The pharmaceutical and biotechnology industries are characterized by rapidly evolving technology and intense competition. The company's oncology product candidates compete with all other oncology products being developed for the indications that it is focusing on.

Comparison to Industry Standards

• Only three OV products have been approved in different global markets: Amgen Inc.'s Imlygic (T-VEC, OncoVEX) for melanoma (USA); Daiichi Sankyo Company, Limited's DELYTACT for malignant glioma (Japan) and Shanghai Sunway Biotech Co., Ltd Oncorine for patients with late-stage refractory nasopharyngeal cancer (China).
• A BLA filed by Replimune, Inc. for their OV RP1 (vusolimogene oderparepvec) in combination with nivolumab for patients with advanced melanoma has been accepted by the FDA with a Prescription Drug User Fee Act (PDUFA) action date of July 22, 2025.
• In June 2024, CG Oncology, Inc. announced that their Phase 3 OV cretostimogene grenadenorepvec was available in the U.S. for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) who meet certain program eligibility criteria.
• More than 60 companies have publicly identified that they are pursuing clinical development of different forms of OV products.

Related Party Transactions

• On December 13, 2024 the Company approved the compensation of MaryAnn Shallcross, the wife of Steven Shallcross, of $157,000 and a bonus of $45,000.

Stakeholder Impact

• The company's financial situation may impact its ability to continue operations and develop new products, potentially affecting shareholders, employees, and patients.
• The company's focus on oncology and development of VCN-01 may benefit patients with pancreatic cancer, retinoblastoma, and other solid tumors.

Next Steps

• The company intends to use the proceeds of the Offering primarily for working capital and general corporate purposes, including for research and development and manufacturing scale-up and may use a portion of the proceeds to invest in or acquire other products, businesses or technologies.
• The company is actively pursuing additional equity or debt financing, in the form of either a private placement or a public offering and has been in ongoing discussions with strategic institutional investors and investment banks with respect to such possible offerings.
• The company will need to obtain additional funding in order to continue the development of certain product candidates within the anticipated time periods (including initiation of planned clinical trials), if at all, and to continue to fund operations at the current cash expenditure levels.

Key Dates

Keywords

VCN-01, oncolytic virus, pancreatic cancer, retinoblastoma, clinical trials, research and development, financial results, Theriva Biologics, SYN-004, SYN-020, FDA, EMA, Orphan Drug Designation, Fast Track Designation